uniQure Reports Wider Q1 Net Loss, Higher Revenue
07:51 AM EDT, 05/10/2021 (MT Newswires) -- uniQure NV (QURE) reported a Q1 net loss Monday of $0.91 per diluted share, wider than a loss of $0.63 a year earlier. Analysts polled by Capital IQ expected a loss of $0.72.
Revenue for the quarter ended March 31 was $454,000, up from $104,000 a year earlier. Analysts polled by Capital IQ expected $1.9 million.
The gene therapy company said its cash position was $260.8 million as of March 31, which didn't include any financial impact associated with a commercialization and license agreement with CSL Behring. Including receipt from CSL Behring of the $450 million upfront payment for the agreement, the company said it expects cash and cash equivalents will be sufficient to fund operations into the second half of 2024.
Price: 32.56, Change: +0.01, Percent Change: +0.03